For the year ending 2025-12-31.
| Income Statement | 2025-12-31 | |||
|---|---|---|---|---|
| Research and development | 14,290 | |||
| General and administrative | 5,795 | |||
| Total operating expenses | 20,085 | |||
| Total operating loss | -20,085 | |||
| Interest income | 126 | |||
| Interest expense | 7,329 | |||
| Change in fair value of derivatives | -3,548 | |||
| Total other expense | -10,751 | |||
| Net loss | -30,836 | |||
| Preferred stock dividends | 138 | |||
| Net loss applicable to common stockholders | -30,974 | |||
| Basic EPS | -0.48 | |||
| Diluted EPS | -0.48 | |||
| Basic Average Shares | 63,903,000 | |||
| Diluted Average Shares | 63,903,000 | |||
GALECTIN THERAPEUTICS INC (GALT)
GALECTIN THERAPEUTICS INC (GALT)